Skip to main content

Advertisement

Log in

Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

The high incidence of infectious complications in ulcerative colitis (UC) is generally recognized to be due to several factors related to a compromised host. In our previous study, a high dose of corticosteroid was shown to be a risk factor for surgical site infection (SSI). Recently, infliximab (IFX) has been used for refractory UC. In this study, the effect of IFX on the occurrence of infectious postoperative complications for UC was evaluated, because it remains controversial.

Method

A total of 196 UC patients who underwent laparotomy between January 2010 and September 2012 were included. Possible factors related to complications were analyzed to identify significant predictors.

Results

Twenty-two patients had IFX before surgery. The overall incidence of SSI was 47/196 (24.0 %). The incidence of infections, including SSI and other infections, was 69/196 (35.2 %). On multivariate analysis, national nosocomial infection surveillance (NNIS) risk index ≥2 (p<0.01) and preoperative prednisolone dose ≥0.2 mg/kg/day (p = 0.01) were identified as independent risk factors for overall SSI; NNIS risk index ≥2 (p <0.01) and duration from onset of UC ≥6.3 years (p = 0.045) were identified as independent risk factors for incisional SSI; contaminated wound class (p <0.01), preoperative hospital stay ≥6 days (p = 0.048), severe/fulminant disease activity (p = 0.04), and pancolitis (p = 0.02) were identified as independent risk factors for organ/space SSI; and contaminated wound (p < 0.01), severe/fulminant disease activity (p = 0.02), and age at surgery ≥43 years (p = 0.047) were identified as independent risk factors for total infectious complications.

Conclusion

IFX administration was not associated with infectious complications for UC surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Langholz E, Munkholm P, Davidsen M, Binder V (1992) Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 103:1444–1451

    PubMed  CAS  Google Scholar 

  2. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476

    Article  PubMed  CAS  Google Scholar 

  3. Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T (2010) Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol 25:886–891

    Article  PubMed  CAS  Google Scholar 

  4. Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ (2004) Early postoperative complications are not increased in patients with Crohn’s disease treated preoperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99:878–883

    Article  PubMed  CAS  Google Scholar 

  5. Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A (2002) Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123:707–713

    Article  PubMed  CAS  Google Scholar 

  6. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, Hiele M, Bueno De Mesquita M, D'Hoore A, Penninckx F, Rutgeerts P (2004) The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 19:749–754

    Article  PubMed  CAS  Google Scholar 

  7. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956–962

    Article  PubMed  Google Scholar 

  8. Mor IJ, Vogel JD, da Luz MA, Shen B, Hammel J, Remzi FH (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1202–1210

    Article  PubMed  CAS  Google Scholar 

  9. Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M (2011) A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 6:1000–1012

    Article  Google Scholar 

  10. Yang Z, Wu Q, Wu K, Fan D (2010) Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 31:486–492

    Article  PubMed  CAS  Google Scholar 

  11. Uchino M, Ikeuchi H, Matsuoka H, Tsuchida T, Tomita N, Takesue Y (2010) Risk factors associated with surgical site infection after ileal pouch-anal anastomosis in ulcerative colitis. Dis Colon Rectum 53:143–149

    Article  PubMed  Google Scholar 

  12. Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15:463–473

    Article  PubMed  CAS  Google Scholar 

  13. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 13:606–608

    Article  PubMed  CAS  Google Scholar 

  14. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections. Am J Infect Control 16:128–140

    Article  PubMed  CAS  Google Scholar 

  15. Truelove SC, Witts LJ (1955) Cortison in ulcerative colitis. Final report on a therapeutic trial. Br Med J 2:1041–1045

    Article  PubMed  CAS  Google Scholar 

  16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections. Am J Infect Control 16:128–140

    Article  PubMed  CAS  Google Scholar 

  17. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309–332

    Article  PubMed  Google Scholar 

  18. Sandborn WJ, Loftus EV (2004) Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 53:780–782

    Article  PubMed  CAS  Google Scholar 

  19. Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ (2004) Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99:878–883

    Article  PubMed  CAS  Google Scholar 

  20. den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, de Waal-Malefijt M, van den Hoogen FH (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34:689–695

    Google Scholar 

  21. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956–962

    Article  PubMed  Google Scholar 

  22. Mor IJ, Vogel JD, da Luz MA, Shen B, Hammel J, Remzi FH (2008) Infliximab in ulcerative colitis is associated with an increasing risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1201–1210

    Article  Google Scholar 

  23. Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M (2011) A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 6:1000–1012

    Article  Google Scholar 

  24. Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15:463–473

    Article  PubMed  CAS  Google Scholar 

  25. Lim M, Sagar P, Abdulgader A, Thekkinkattil D, Burke D (2007) The impact of preoperative immunomodulation on pouch-related septic complications after ileal pouch-anal anastomosis. Dis Colon Rectum 50:943–951

    Article  PubMed  Google Scholar 

  26. Ahn HS, Lee SK, Kim HJ, Jang JY, Joo KR, Dong SH, Kim BH, Lee JI, Chang YW, Chang R (2006) Risk of postoperative infection in patients with inflammatory bowel disease. Korean J Gastroenterol 48:306–312

    PubMed  Google Scholar 

  27. Miki C, Ohmori Y, Yoshiyama S, Toiyama Y, Araki T, Uchida K, Kusunoki M (2007) Factors predicting postoperative infectious complications and early induction of inflammatory mediators in ulcerative colitis patients. World J Surg 31:522–529

    Article  PubMed  Google Scholar 

  28. Subramanian V, Pollok RC, Kang JY, Kumar D (2006) Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 93:793–799

    Article  PubMed  CAS  Google Scholar 

  29. Petrosillo N, Drapeau CM, Nicastri E, Martini L, Ippolito G, Moro ML et al (2008) Surgical site infections in Italian hospitals: a prospective multicenter study. BMC Infect Dis 8:34

    Article  PubMed  Google Scholar 

  30. Edwards JP, Ho AL, Tee MC, Dixon E, Ball CG (2012) Wound protectors reduce surgical site infection: a meta-analysis of randomized controlled trials. Ann Surg 256:53–59

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

We have no disclosures or funding related to this study to declare.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Motoi Uchino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uchino, M., Ikeuchi, H., Matsuoka, H. et al. Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis. Int J Colorectal Dis 28, 1295–1306 (2013). https://doi.org/10.1007/s00384-013-1700-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-013-1700-2

Keywords

Navigation